Collaboration

  • Home 
  • > Technology > 
  • Collaboration

Representative oncology drugs for HCC under clinical trial

Molecular
targeted drug
Immuno-oncology drug Cytotoxic drug Others
TKI Levantinib Nivolumab (anti-PD-1) CBSFlatin (Cisplatin) JX-594 (virus)
Refametinib Tremelimumab Thermodox (Doxorubicin) miR-221 (microRNA)
(anti-CTLA-4)
LY2157299   Livatag (Doxorubicin) G-202 (peptide)
Regorafenib WELCOME ANY CHANCE TO COLLABORATION
FOR CO-DEVELOPMENT OF DRUG AND CDx
Tivantinib
INC280
Cabozantinib
Axitinib
Erlotinib
HDACi Resminostat
Belinostat

WELCOME ANY CHANCE TO COLLABORATION !!

Collaboration advantages

1 KCBC : Network of Hepatologists, Surgeons and Physicians in Korea
2 Performing biopsy for gene expression analysis
in a study trial or routine practice
3 Much lower budget for a clinical trial in Korea
4 Our experience in regulatory affairs for approval of in vitro diagnostics and
investigational new drug with Korea FDA